|
|
| |
|
|
|
|
Biopartners GmbH| Adress: | Sihlbruggstrasse 3
6340 Baar | | Phone: | +41 41 766 20 80 | | Fax: | +41 41 766 20 81 | | Website: | www.biopartners.com | | | | | Contact: | Dr. Conrad Savoy, President and CEO | | Products and services: | Once-a-week human growth hormone treatment with an innovative prolonged release formulation. We are on track to be the first company to submit for registration a prolonged-release formulation of recombinant human growth hormone (rhGH) which will cut the number of self-administered injections from once-a-day to once-a-week, a major breakthrough in hGH treatment.
Biopartners also holds an EU marketing authorization for Ribavirin BioPartners 200 mg film-coated tablets.
Biopartners has a beta-interferon under development for use in multiple sclerosis (Phase III).
| | Year of Foundation: | 2000 | | Persons employed in Switzerland: | 10-19 | | How many in Biotechnology: | 1-9 | | Classification: | Biotech Company
| | Key Business in Switzerland: | | | Biotech Activities: | Pharmaceuticals / Therapeutics / Vaccines (human)
| | Production in Switzerland: | no | | Research & Development: | We are a dynamic and growing biopharmaceutical company developing biopharmaceutical products in the fields of endocrinology, multiple sclerosis and virology. Biopartners is dedicated to improving quality of life through significant advancements in patient care. Our advanced product portfolio consists of first-generation biopharmaceuticals with innovative-formulations or novel delivery systems. | | Cooperation possibilities: | Commercial agreements for the distribution of Biopartners' products in all relevant markets.
Contribution to development activities, including medical device/new technologies to further optimize the potential of the products and to deliver added benefits to patients.
|
<- Zurück |
|
|
|
